|
|
|
 |
|
 |
 |
|||
Company News
|
Astex Announces New Licensing and Drug Discovery Alliance to Develop Novel Cell Cycle Cancer Drugs
Cambridge, UK, 06 December 2005
top
Syntaxin launched in spin out of medicines discovery programme from UK Health Protection Agency
Salisbury, UK, 14 November 2005
top
Fovea Pharmaceuticals completes a €20.5 million ($25 million) Series A financing to develop new drugs for retinal diseases
Paris, France, 07 November 2005
top
Phoqus Pharmaceuticals Group Limited
London, UK, 31 October 2005
top
Affymetrix Completes Acquisition of ParAllele BioScience; Companies Combine Their Innovative Technologies to Enable Advances in
SANTA CLARA, California, 24 October 2005
top
Celldex Announces Acquisition of Lorantis Limited and Assets of Alteris Therapeutics, Inc.
Bloomsbury, N.J., 20 October 2005
top
Abingworth appoints David Pinniger
London, 21 September 2005
top
Novartis and Alnylam Create Major Alliance to Discover RNAi Therapeutics
CAMBRIDGE, Mass, 07 September 2005
top
Adiana, Inc. Reports Completion of $23 Million Financing
Redwood City, California, 25 August 2005
top
AstraZeneca and Astex announce new anti-cancer drug discovery alliance
Cambridge, UK, 27 July 2005
top
Labcyte Inc. Closes $21 Million Financing with Cross Atlantic Partners Leading
Sunnyvale, CA, 25 July 2005
top
Abingworth appoints Tim Haines as Partner
London, UK, 20 July 2005
top
Abingworth raises new life sciences public equities fund
London, UK, 18 July 2005
top
Devgen raises € 30 million in successful IPO
Ghent, Belgium, 05 June 2005
top
Galapagos raises additional € 2.0 million in IPO
Mechelen, Belgium, 03 June 2005
top
ParAllele BioScience Signs Agreement to be Acquired by Affymetrix
South San Francisco, CA, 31 May 2005
top
Oxagen Limited Raises $59.8 Million in Series B Private Venture Capital Financing Led by MPM Capital
Abingdon, UK, 23 May 2005
top
Abingworth opens East Coast office and appoints Dr Roy Lobb
London, UK, and Waltham, MA, US, 10 May 2005
top
Galapagos raises €20 million with IPO on Euronext Brussels and Euronext Amsterdam
Mechelen, Belgium, 05 May 2005
top
Lynx and Solexa Ltd Combine to Become Solexa, Inc.
Company Plans to Dramatically Reduce Cost of Whole Genome DNA Sequencing & Gene Expression Measurement
Cambridge, UK, 07 March 2005
top
Alexza MDC Raises $52 Million in Series D Financing
Palo Alto, CA, 06 January 2005
top
|
Archive:
|
|||||||||||||||||||||||||||||||||||||||||||||
2013
Andrew Kay, President and CEO of Algeta
Abingworth set a highly professional tone from the beginning. The due diligence was detailed and incisive and this attention to detail continued as Algeta became one of their portfolio companies. It is Abingworth's support capability that really distinguishes them. This includes market analytics, finance, commercial intelligence, and search expertise for executive managers and board members. They have extensive networks with big companies, biotechs and banks that provides invaluable introductions and contacts. What is quite remarkable is that despite being one of many portfolio companies, everyone across the Abingworth organisation seems to know who you are and they are responsive and enthusiastic about thinking of ways to help, identifying opportunities, issues and solutions.